In a phase 1&2 clinical trial, KEYNOTE-021, the analysis of cohorts D and H showed that pembrolizumab (anti-PD1) combined with ipilimumab therapy increased the anti-tumor activity, compared with a single agent, in pretreated advanced NSCLC patients [71]. The gene discussed is PDCD1; the disease is neoplasm.